Glucose homeostasis in rainbow trout fed a high-carbohydrate diet: metformin and insulin interact in a tissue-dependent manner.
Carnivorous fish species such as the rainbow trout (Oncorhynchus mykiss) are considered to be "glucose intolerant" because of the prolonged hyperglycemia experienced after intake of a carbohydrate-enriched meal. In the present study, we use this species to study glucose homeostasis in fish chronically infused with the hypoglycemic agents, insulin, and metformin, and fed with a high proportion of carbohydrates (30%). We analyzed liver, skeletal muscle, and white adipose tissue (WAT), which are insulin- and metformin-specific targets at both the biochemical and molecular levels. Trout infused with the combination of insulin and metformin can effectively utilize dietary glucose at the liver, resulting in lowered glycemia, increased insulin sensitivity, and glucose storage capacity, combined with reduced glucose output. However, in both WAT and skeletal muscle, we observed decreased insulin sensitivity with the combined insulin + metformin treatment, resulting in the absence of changes at the metabolic level in the skeletal muscle and an increased potential for glucose uptake and storage in the WAT. Thus, the poor utilization by rainbow trout of a diet with a high proportion of carbohydrate can at least be partially improved by a combined treatment with insulin and metformin, and the glucose intolerance observed in this species could be, in part, due to some of the downstream components of the insulin and metformin signaling pathways. However, the predominant effects of metformin treatment on the action of insulin in these three tissues thought to be involved in glucose homeostasis remain exclusive in this species.
Institut National de la Recherche Agronomique, UMR Nutrition Aquaculture et Génomique, Saint-Pée-sur-Nivelle, France. spolakof@st-pee.inra.fr
S
S
Polakof
T W
TW
Moon
P
P
Aguirre
S
S
Skiba-Cassy
S
S
Panserat
D052436:Adipose Tissue, White / Q000378:metabolism; D000284:Administration, Oral; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D004040:Dietary Carbohydrates / Q000008:administration & dosage / Q000494:pharmacology*; D004347:Drug Interactions; D005947:Glucose / Q000378:metabolism*; D006706:Homeostasis / Q000187:drug effects* / Q000502:physiology; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007260:Infusion Pumps; D007328:Insulin / Q000008:administration & dosage / Q000494:pharmacology*; D008099:Liver / Q000378:metabolism; D008687:Metformin / Q000008:administration & dosage / Q000494:pharmacology*; D023421:Models, Animal; D018482:Muscle, Skeletal / Q000378:metabolism; D017686:Oncorhynchus mykiss / Q000378:metabolism*
D001786:Blood Glucose; D004040:Dietary Carbohydrates; D007004:Hypoglycemic Agents; D007328:Insulin; D008687:Metformin; D005947:Glucose